Sleep Apnea’s Billion-Dollar Toll
New analysis links untreated OSA to major productivity losses in working-age adults in the US and UK
By
Jess Allerton
February 25, 2026
Clinical Scorecard: Sleep Apnea’s Billion-Dollar Toll
At a Glance
Category Detail
Condition Obstructive Sleep Apnea (OSA) Key Mechanisms Repeated upper airway obstruction during sleep leading to breathing pauses and excessive daytime sleepiness. Target Population Working-age adults, particularly those aged 18 to 64 years. Care Setting Clinical practice with potential for symptom-based screening.
Key Highlights
Untreated OSA linked to $180.2 billion productivity losses in the US and £4.22 billion in the UK annually. Estimated prevalence of OSA syndrome: 22.8% in the US and 19.5% in the UK. Nearly 30% of US adults aged 18-64 and 7% of UK adults in the same age group meet OSA criteria. Annual productivity loss per affected worker: $3727.40 in the US and approximately £1840 in the UK. Objective sleep testing is essential for diagnosis; symptom-based screening can help identify at-risk individuals. Guideline-Based Recommendations
Diagnosis
Use symptom-based proxies for initial screening. Objective sleep testing is necessary for definitive diagnosis. Management
Continuous positive airway pressure (CPAP) therapy is the primary treatment. Monitoring & Follow-up
Assess adherence to CPAP therapy regularly. Risks
Potential misclassification due to reliance on symptom-based identification. Patient & Prescribing Data
Adults with suspected obstructive sleep apnea.
Adherence to CPAP therapy is often suboptimal despite its effectiveness.
Clinical Best Practices
Implement symptom-based screening in clinical settings to identify at-risk individuals. Encourage adherence to CPAP therapy through patient education and follow-up. References
